Adding more drama to Metsera Inc.’s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50. • Watch the MTSR momentum here.Metsera said the amended proposal constitutes a “Superior Company Proposal.”Additionally, Metsera would issue Novo Nordisk non-voting preferred stock representing 50% of Metsera’s share capital.On the same day, Metsera would declare a dividend of $62.20 per share in cash (up from $56.50).Metsera shareholders co ...

Metsera stock (NASDAQ: MTSR) surged roughly 20% on Tuesday after the obesity-focused biotech announced that Novo Nordisk's revised $10 billion acquisition proposal has been deemed "superior†to Pfizer... ...

We got an oldfashioned bidding war going on between Nova Nordisk and Fizer to take control of Metsera. Our viewers may remember it was last week or actually a few weeks ago Fizer had a deal to acquire this company to try to build its presence uh in the GLP1 arena essentially uh reducing obviously people's uh weight um where it really has not had a great deal of success going up against the incumbents Eli Liy and Nova Nordis. But then Novo came in last week with an interesting offer in terms of its structure ...

TESLA WATCH: Elon Musk Pay Deal In Focus Novo Nordisk (NVO) said it would pay up to $10 billion to acquire obesity-focused Metsera (MTSR), topping Pfizer's (PFE) recently hiked $8.1 billion proposal. The news sent Metsera stock flying more than 15% to 70. Meanwhile, Pfizer stock rose a fraction, while Novo shares gained 1.2%. Pfizer and Metsera have been locked in a heated battle over the last week to buy Metsera. Pfizer's first bid, in September, was for $4.9 billion. Last week, Novo Nordisk made an unsoli ...

此次竞购战聚焦于Metsera的核心资产，旗下处于后期研发阶段的减重及代谢疾病候选药物，被视为继 Wegovy与Zepbound后潜在"下一代爆款"产品。随着全球肥胖治疗市场快速扩张，创新药企正加速卡位 布局。据摩根士丹利测算，到2030年全球减重药物市场规模有望突破千亿美元。 业内人士指出，辉瑞与诺和诺德之争不仅关乎并购溢价，也反映出大型药企正面临专利到期压力与产品 管线补位需求。若辉瑞无法在限期内提出更高报价，不排除提前退出竞争可能。 市场将继续关注未来48小时内辉瑞是否加码投标，以及Metsera董事会最终的交易走向。 智通财经APP获悉，周二，Metsera(MTSR.US)股价走高，截至发稿，该股涨超15%，报70.42美元。消 息面上，来自辉瑞(PFE.US)与诺和诺德(NVO.US)的竞购报价进一步加码。 Metsera当天发表声明称，诺和诺德最新提交的收购提案仍被公司董事会认定为"更具优势"的报价，并 正式通知辉瑞须在两个工作日内提出更优条件，否则将失去竞购资格。 根据最新报价，诺和诺德将收购价格提升至每股总价值86.20美元，交易规模约100亿美元。其中包含每 股62.20美元现金报价（此前 ...

周二，Metsera(MTSR.US)股价走高，截至发稿，该股涨超15%，报70.42美元。消息面上，来自辉瑞 (PFE.US)与诺和诺德(NVO.US)的竞购报价进一步加码。 Metsera当天发表声明称，诺和诺德最新提交的收购提案仍被公司董事会认定为"更具优势"的报价，并 正式通知辉瑞须在两个工作日内提出更优条件，否则将失去竞购资格。 根据最新报价，诺和诺德将收购价格提升至每股总价值86.20美元，交易规模约100亿美元。其中包含每 股62.20美元现金报价(此前为56.50美元)，以及最高24美元/股的或有价值权(此前为21.25美元)，若相关 药物管线达成预设商业化或监管里程碑，股东可额外获得现金收益。 相比之下，辉瑞近期更新的报价最高仅约每股70美元，总价值约81亿美元，明显低于诺和诺德的提案， 也因此被列为"劣势报价"。 此次竞购战聚焦于Metsera的核心资产，旗下处于后期研发阶段的减重及代谢疾病候选药物，被视为继 Wegovy与Zepbound后潜在"下一代爆款"产品。随着全球肥胖治疗市场快速扩张，创新药企正加速卡位 布局。据摩根士丹利测算，到2030年全球减重药物市场规模有望突破千亿美元。 ...

The new offer constitutes a superior company proposal to Pfizer's bid, Metsera said. ...

The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy is seen outside theri building as the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025.Metsera on Tuesday said Novo Nordisk's new bid for the obesity biotech is "superior" to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. Novo Nordisk's new proposal values Metsera at up to $86. ...

Novo Nordisk and Pfizer have revised their bids for Metsera , the obesity drug developer said on Tuesday. ...

Accessibility StatementSkip Navigation Novo Nordisk Amended Proposal Values Metsera at up to $ 86.20 per Share, a Total of Approximately $ 10.0 Billion Pfizer Merger Agreement Remains in Effect; No Action Required by Metsera Shareholders Superior to Revised Pfizer Proposal that Valued Metsera at up to $ 70.00 per Share, a Total of Approximately $ 8.1 Billion Pursuant to Pfizer Merger Agreement, Metsera and Pfizer May Negotiate Potential Adjustments for Two Business Days NEW YORK, Nov. 4, 2025 /PRNewswire/ - ...